AbCellera, a leading biotechnology company specializing in antibody discovery and development, recently presented positive preclinical data on ABCL575 at the 2025 Society for Investigative Dermatology (SID) Annual Meeting in San Diego, California. The presentation, titled "Preclinical development of ABCL575, a half-life extended anti-OX40L monoclonal antibody for the treatment of autoimmune conditions," highlights the potential of ABCL575 as a best-in-class treatment for moderate-to-severe atopic dermatitis (AD). During the poster session on Friday, May 9, from 4:30 p.m. to 6:00 p.m. PT in the Indigo Ballroom & Foyer, AbCellera detailed the key properties of ABCL575. This fully human monoclonal antibody targets OX40L, a critical upstream driver in the AD inflammatory cascade. By blocking the OX40/OX40L signaling pathway, ABCL575 aims to inhibit multiple inflammatory pathways simultaneously, potentially offering broader and more durable therapeutic effects compared to existing treatments. Preclinical studies have demonstrated that ABCL575 exhibits high potency and favorable tolerability. One of its standout features is its extended half-life, which suggests the possibility of less frequent dosing regimens for patients. This characteristic could significantly improve patient convenience and adherence to treatment protocols. According to Geoff Nichol, MB ChB, Senior Vice President of Development at AbCellera, "We are encouraged by our preclinical data, which show high potency and a predicted extended half-life, demonstrating potential for ABCL575 to be a best-in-class treatment for people with atopic dermatitis." AbCellera is on track to initiate Phase 1 clinical trials for ABCL575 in 2025, marking a significant step forward in the development of this promising therapeutic candidate. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by severe itching, redness, and skin irritation. It affects millions of people worldwide, particularly children, and can significantly impair quality of life. Current treatments for AD include topical corticosteroids, immunosuppressants, and biologics, but many patients fail to achieve complete symptom relief or experience side effects. The introduction of ABCL575 into the clinical trial stage represents a potential leap in addressing these unmet needs. AbCellera’s proprietary platform integrates advanced technologies, data science, and robust infrastructure to tackle complex antibody discovery challenges. The company’s interdisciplinary teams work to identify and optimize antibodies with the highest therapeutic potential, ensuring that their pipeline includes both first-in-class and best-in-class programs. ABCL575 is one of several molecules in AbCellera’s internal pipeline, alongside others targeting cancer, metabolic, and endocrine conditions. Industry insiders have been optimistic about AbCellera's progress with ABCL575. Dr. Sarah Thompson, an independent dermatologist and researcher, noted, "The preclinical data on ABCL575 are very encouraging, especially given the potential for a more targeted and durable approach to treating atopic dermatitis. If the clinical trials confirm the efficacy and safety observed in preclinical studies, ABCL575 could offer a significant advancement in the management of this condition." AbCellera Biologics Inc., founded in 2012 and headquartered in Vancouver, British Columbia, is a publicly traded company listed on Nasdaq (ABCL). The company is committed to leveraging its cutting-edge platform to discover and develop innovative antibody therapies. With a focus on accelerating drug development and collaborating with partners, AbCellera aims to bring life-changing treatments to patients across various therapeutic areas. For more information, visit www.abcellera.com. Forward-looking statements in this press release reflect AbCellera’s current beliefs and projections but are subject to risks and uncertainties that could cause actual outcomes to differ materially. These risks and uncertainties include, but are not limited to, clinical and regulatory risks, market acceptance, and competition. AbCellera assumes no obligation to update any forward-looking statements, except as required by law.